Transforming growth factor-β plays divergent roles in modulating vascular remodeling, inflammation, and pulmonary fibrosis in a murine model of scleroderma

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 312, Issue 1, 2017, Pages L22-L31

  Tsujino, Kazuyuki ^a   Reed, Nilgun Isik ^a   Atakilit, Amha ^a   Ren, Xin ^a   Sheppard, Dean ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Fibrosis; Inflammation; Systemic sclerosis; Transforming growth factor ; Vasculopathy

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BMPR2 PROTEIN; PROTEIN; TAMOXIFEN; TRANSCRIPTION FACTOR FRA 2; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; UNCLASSIFIED DRUG; ACTA2 PROTEIN, MOUSE; ACTIN; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; FOSL2 PROTEIN, MOUSE; PROTEIN SERINE THREONINE KINASE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR-BETA TYPE II RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DISEASE SEVERITY; GENE DELETION; GRANULOCYTE; HISTOLOGY; IMMUNOHISTOCHEMISTRY; LOSS OF FUNCTION MUTATION; LUNG ALVEOLUS; LUNG FIBROSIS; MOUSE; MYOFIBROBLAST; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY ARTERY SMOOTH MUSCLE CELL; SCLERODERMA; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CELL; VASCULAR REMODELING; VASCULAR SMOOTH MUSCLE CELL; ANIMAL; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; GENETICS; METABOLISM; PATHOLOGY; SYSTEMIC SCLEROSIS; TRANSGENIC MOUSE; VASCULAR DISEASE;

ACTINS; ANIMALS; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE II; DISEASE MODELS, ANIMAL; FOS-RELATED ANTIGEN-2; GENE DELETION; GRANULOCYTES; MICE, TRANSGENIC; MYOCYTES, SMOOTH MUSCLE; PNEUMONIA; PROTEIN-SERINE-THREONINE KINASES; PULMONARY ALVEOLI; PULMONARY FIBROSIS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; VASCULAR DISEASES; VASCULAR REMODELING;

EID: 85008319915     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00428.2016     Document Type: Article

References (41)

1. Asano Y, Sato S. Animal models of scleroderma: current state and recent development. Curr Rheumatol Rep 15: 382, 2013.
2. Banchereau J, Pascual V, O’Garra A. From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines. Nat Immunol 13: 925-931, 2012.
3. Botney MD, Bahadori L, Gold LI. Vascular remodeling in primary pulmonary hypertension. Potential role for transforming growth factor-β. Am J Pathol 144: 286-295, 1994.
4. Bringardner BD, Baran CP, Eubank TD, Marsh CB. The role of inflammation in the pathogenesis of idiopathic pulmonary fibrosis. Antioxid Redox Signal 10: 287-301, 2008.
5. Carvalho RL, Itoh F, Goumans MJ, Lebrin F, Kato M, Takahashi S, Ema M, Itoh S, van Rooijen M, Bertolino P, Ten Dijke P, Mummery CL. Compensatory signalling induced in the yolk sac vasculature by deletion of TGFreceptors in mice. J Cell Sci 120: 4269-4277, 2007.
6. Condliffe R, Kiely DG, Peacock AJ, Corris PA, Gibbs JS, Vrapi F, Das C, Elliot CA, Johnson M, DeSoyza J, Torpy C, Goldsmith K, Hodgkins D, Hughes RJ, Pepke-Zaba J, Coghlan JG. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 179: 151-157, 2009.
7. Dasch JR, Pace DR, Waegell W, Inenaga D, Ellingsworth L. Monoclonal antibodies recognizing transforming growth factor-β. Bioactivity neutralization and transforming growth factor-β2 affinity purification. J Immunol 142: 1536-1541, 1989.
8. Denton CP, Merkel PA, Furst DE, Khanna D, Emery P, Hsu VM, Silliman N, Streisand J, Powell J, Akesson A, Coppock J, Hoogen F, Herrick A, Mayes MD, Veale D, Haas J, Ledbetter S, Korn JH, Black CM, Seibold JR. Recombinant human anti-transforming growth factor-β1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 56: 323-333, 2007.
9. Eferl R, Hasselblatt P, Rath M, Popper H, Zenz R, Komnenovic V, Idarraga MH, Kenner L, Wagner EF. Development of pulmonary fibrosis through a pathway involving the transcription factor Fra-2/AP-1. Proc Natl Acad Sci USA 105: 10525-10530, 2008.
10. Gifford AH, Matsuoka M, Ghoda LY, Homer RJ, Enelow RI. Chronic inflammation and lung fibrosis: pleotropic syndromes but limited distinct phenotypes. Mucosal Immunol 5: 480-484, 2012.
11. Gilbane AJ, Derrett-Smith E, Trinder SL, Good RB, Pearce A, Denton CP, Holmes AM. Impaired bone morphogenetic protein receptor II signaling in a transforming growth factor-β-dependent mouse model of pulmonary hypertension and in systemic sclerosis. Am J Respir Crit Care Med 191: 665-677, 2015.
12. Goumans MJ, Liu Z, ten Dijke P. TGF-β signaling in vascular biology and dysfunction. Cell Res 19: 116-127, 2009.
13. Graham BB, Chabon J, Gebreab L, Poole J, Debella E, Davis L, Tanaka T, Sanders L, Dropcho N, Bandeira A, Vandivier RW, Champion HC, Butrous G, Wang XJ, Wynn TA, Tuder RM. Transforming growth factor- signaling promotes pulmonary hypertension caused by Schistosoma mansoni. Circulation 128: 1354-1364, 2013.
14. v-integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat Med 19: 1617-1624, 2013.
15. Hudnall AM, Arthur JW, Lowery JW. Clinical relevance and mechanisms of antagonism between the BMP and activin/TGF-signaling pathways. J Am Osteopath Assoc 116: 452-461, 2016.
16. Kashima R, Roy S, Ascano M, Martinez-Cerdeno V, Ariza-Torres J, Kim S, Louie J, Lu Y, Leyton P, Bloch KD, Kornberg TB, Hagerman PJ, Hagerman R, Lagna G, Hata A. Augmented noncanonical BMP type II receptor signaling mediates the synaptic abnormality of fragile X syndrome. Sci Signal 9: ra58, 2016.
17. Ke Q, Li W, Lai X, Chen H, Huang L, Kang Z, Li K, Ren J, Lin X, Zheng H, Huang W, Ma Y, Xu D, Chen Z, Song X, Zhuang M, Wang T, Zhuang F, Xi J, Mao FF, Xia H, Lahn BT, Zhou Q, Yang S, Xiang AP. TALEN-based generation of a cynomolgus monkey disease model for human microcephaly. Cell Res 26: 1048-1061, 2016.
18. Kolahian S, Fernandez IE, Eickelberg O, Hartl D. Immune mechanisms in pulmonary fibrosis. Am J Respir Cell Mol Biol 53: 309-322, 2016.
19. Leveen P, Larsson J, Ehinger M, Cilio CM, Sundler M, Sjostrand LJ, Holmdahl R, Karlsson S. Induced disruption of the transforming growth factor-β type II receptor gene in mice causes a lethal inflammatory disorder that is transplantable. Blood 100: 560-568, 2002.
20. Li W, Li Q, Jiao Y, Qin L, Ali R, Zhou J, Ferruzzi J, Kim RW, Geirsson A, Dietz HC, Offermanns S, Humphrey JD, Tellides G. Tgfbr2 disruption in postnatal smooth muscle impairs aortic wall homeostasis. J Clin Invest 124: 755-767, 2014.
21. Liu W, Zhou L, Zhou C, Zhang S, Jing J, Xie L, Sun N, Duan X, Jing W, Liang X, Zhao H, Ye L, Chen Q, Yuan Q. GDF11 decreases bone mass by stimulating osteoclastogenesis and inhibiting osteoblast differentiation. Nat Commun 7: 12794, 2016.
22. Long L, Crosby A, Yang X, Southwood M, Upton PD, Kim DK, Morrell NW. Altered bone morphogenetic protein and transforming growth factor-β signaling in rat models of pulmonary hypertension: potential for activin receptor-like kinase-5 inhibition in prevention and progression of disease. Circulation 119: 566-576, 2009.
23. Ma L, Chung WK. The genetic basis of pulmonary arterial hypertension. Hum Genet 133: 471-479, 2014.
24. Madisen L, Zwingman TA, Sunkin SM, Oh SW, Zariwala HA, Gu H, Ng LL, Palmiter RD, Hawrylycz MJ, Jones AR, Lein ES, Zeng H. A robust and high-throughput Cre reporting and characterization system for the whole mouse brain. Nat Neurosci 13: 133-140, 2010.
25. Maurer B, Reich N, Juengel A, Kriegsmann J, Gay RE, Schett G, Michel BA, Gay S, Distler JH, Distler O. Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis. Ann Rheum Dis 71: 1382-1387, 2012.
26. Newman JH, Phillips JA 3rd, Loyd JE. The enigma of pulmonary arterial hypertension: new insights from genetic studies. Ann Intern Med 148: 278-283, 2008.
27. Prud’homme GJ. Pathobiology of transforming growth factor-in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab Invest 87: 1077-1091, 2007.
28. Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest 122: 4306-4313, 2012.
29. 1-integrin plays a critical in vivo role in tissue fibrosis. Sci Transl Med 7: 288ra279, 2015.
30. Reich N, Maurer B, Akhmetshina A, Venalis P, Dees C, Zerr P, Palumbo K, Zwerina J, Nevskaya T, Gay S, Distler O, Schett G, Distler JH. The transcription factor Fra-2 regulates the production of extracellular matrix in systemic sclerosis. Arthritis Rheum 62: 280-290, 2010.
31. Rock JR, Barkauskas CE, Cronce MJ, Xue Y, Harris JR, Liang J, Noble PW, Hogan BL. Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial-to-mesenchymal transition. Proc Natl Acad Sci USA 108: E1475-E1483, 2011.
32. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 66: 940-944, 2007.
33. Sun KH, Chang Y, Reed NI, Sheppard D. α-Smooth muscle actin is an inconsistent marker of fibroblasts responsible for force-dependent TGF-β activation or collagen production across multiple models of organ fibrosis. Am J Physiol Lung Cell Mol Physiol 310: L824-L836, 2016.
34. vβ8 on dendritic cells causes autoimmunity and colitis in mice. Nature 449: 361-365, 2007.
35. Tsujino K, Sheppard D. Critical appraisal of the utility and limitations of animal models of scleroderma. Curr Rheumatol Rep 18: 4, 2016.
36. Tsujino K, Takeda Y, Arai T, Shintani Y, Inagaki R, Saiga H, Iwasaki T, Tetsumoto S, Jin Y, Ihara S, Minami T, Suzuki M, Nagatomo I, Inoue K, Kida H, Kijima T, Ito M, Kitaichi M, Inoue Y, Tachibana I, Takeda K, Okumura M, Hemler ME, Kumanogoh A. Tetraspanin CD151 protects against pulmonary fibrosis by maintaining epithelial integrity. Am J Respir Crit Care Med 186: 170-180, 2012.
37. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 117: 557-567, 2007.
38. Varga J, Pasche B. Transforming growth factor-β as a therapeutic target in systemic sclerosis. Nat Rev Rheumatol 5: 200-206, 2009.
39. Wendling O, Bornert JM, Chambon P, Metzger D. Efficient temporally-controlled targeted mutagenesis in smooth muscle cells of the adult mouse. Genesis 47: 14-18, 2009.
40. Worthington JJ, Fenton TM, Czajkowska BI, Klementowicz JE, Travis MA. Regulation of TGFβ in the immune system: an emerging role for integrins and dendritic cells. Immunobiology 217: 1259-1265, 2012.
41. Yung LM, Nikolic I, Paskin-Flerlage SD, Pearsall RS, Kumar R, Yu PB. A selective TGFβ ligand trap attenuates pulmonary hypertension. Am J Respir Crit Care Med 194: 1140-1151, 2016.